A case of cutaneous blastic plasmacytoid dendritic cell neoplasm

Acta Dermato-Venereologica

Volumn 90, Issue 6, 2010, Pages 645-646

  Xue, Ruzeng ^a   Wu, Tieqiang ^a   Pan, Huiqing ^a   Gu, Youshou ^a   Yang, Bin ^a   Chen, Yongfeng ^a   Qiu, Jushi ^b  

^a Guangdong Provincial Center for Skin Diseases and STD Control   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD123 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD99 ANTIGEN; CHLORDANE; CORTICOSTEROID; DNA NUCLEOTIDYLEXOTRANSFERASE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LEUKOSIALIN; MYELOPEROXIDASE; PREDNISONE;

ADULT; BLAST CELL; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; BLOOD ANALYSIS; CASE REPORT; ECZEMA; EPSTEIN BARR VIRUS; GIEMSA STAIN; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; LETTER; MALE; MAST CELL; PHYSICAL EXAMINATION; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SKIN BIOPSY; SKIN LYMPHOMA; SKIN NODULE;

ADULT; BIOPSY; DENDRITIC CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 78649708006     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0922     Document Type: Letter

References (11)

1. th edn. Lyon: IARC Press, 2008: p. 145-147.
2. Petrella T, Meijer CJ, Dalac S, Willemze R, Maynadié M, Machet L, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol 2004; 122: 307-313.
3. Jaffe ES, Harris NL, Stein H, Vardiman JW. World health organization classification of tumours: tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001, p. 214-215.
4. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
5. Kaune KM, Baumgart M, Bertsch HP, Mitteldorf C, Müller-Hermelink HK, Haase D, et al. Solitary cutaneous nodule of blastic plasmacytoid dendritic cell neoplasm progressing to overt leukemia cutis after chemotherapy: immunohistology and FISH analysis confirmed the diagnosis. Am J Dermatopathol 2009; 31: 695-701.
6. Petrella T, Dalac S, Maynadie M, Mugneret F, Thomine E, Courville P, et al. CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC). Am J Surg Pathol 1999; 23: 137-146.
7. Wiesner T, Obenauf AC, Cota C, Fried I, Speicher MR, Cerroni L. Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid Dendritic cell neoplasms. J Invest Dermatol 2010; 130: 1152-1157.
8. Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 2010; 162: 74-79.
9. Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 2005; 123: 662-675.
10. Feuillard J, Jacob MC, Valensi F, Maynadié M, Gressin R, Chaperot L, et al. Clinical and biologic features of CD4(+) CD56(+) malignancies. Blood 2002; 99: 1556-1563.
11. Reimer P, Rüdiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant 2003; 32: 637-646.